Skip to main content

Table 7 Comparison of baseline CPG domain scores versus 6, 12 and 18 month visits. Values are expressed as median (range) with respective p values

From: A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

 Baseline6 mp12 mp18 mp24 mp
Pain intensity66.6 (30–93)39.9 (0–83.3)0.00130
(0–76.7)
<  0.00130 (0–73.3)p <  0.00113.33
(0–36.3)
<  0.001
Disability60
(16–113)
16.7 (0–93.3)0.0020 (0–66.7)< 0.0010 (0–63.3)p < 0.0010 (0–63)0.001
Pain grade3 (1–4)1 (0–4)0.0040 (0–4)0.0010 (0–4)p < 0.0010 (0–4).0.002